Agerafenib

DB15068InvestigationalSmall molecule

Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

Mechanism: Pharmacologically active on Epidermal growth factor receptor, Proto-oncogene tyrosine-protein kinase receptor Ret, and Serine/threonine-protein kinase B-raf
Curator reviewed
Formula / weight: C₂₄H₂₂F₃N₅O₅ · 517.465 g/mol (avg)
Code names: RXDX-105

Resolves to

Compound

Structure

InChIKeyDKNUPRMJNUQNHR-UHFFFAOYSA-NSMILESCOC1=C(OC)C=C2C(OC3=CC=CC(NC(=O)NC4=NOC(=C4)C(C)(C)C(F)(F)F)=C3)=NC=NC2=C1

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Agerafenib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.